Falsified and Substandard Drugs: Stopping the Pandemic

Area of Science:

• Global Health
• Pharmaceutical Sciences
• Public Policy

Background:

• Falsified and substandard medicines lead to tens of thousands of deaths annually, primarily affecting children in low-income nations.
• Poor-quality drugs result in substantial economic losses, estimated up to US$200 billion yearly.
• These medicines exacerbate the growing threat of antimicrobial resistance.

Purpose of the Study:

• To highlight the critical global issue of falsified and substandard medicines.
• To emphasize the need for enhanced efforts in research, policy, and field monitoring.
• To advocate for strengthened international and national pharmaceutical governance.

Main Methods:

• Review of the impact of poor-quality drugs on global health and economy.
• Analysis of the role of the World Health Organization (WHO) and pharmaceutical companies.
• Identification of current gaps and future priorities in combating counterfeit medicines.

Main Results:

• The World Health Organization (WHO) is a key player in combating poor-quality drugs.
• Pharmaceutical companies are increasingly involved in ensuring drug supply chain integrity.
• Despite technological advances, significant challenges remain in drug quality surveillance.

Conclusions:

• Further research, robust policy development, and diligent field monitoring are essential.
• Strengthening pharmaceutical governance through international and national measures is crucial.
• Establishing a quantifiable Sustainable Development Goal target and an international convention for drug quality and safety is an urgent priority.